Literature DB >> 28703360

Model averaging for robust assessment of QT prolongation by concentration-response analysis.

A G Dosne1, M Bergstrand1, M O Karlsson1, D Renard2, G Heimann2.   

Abstract

Assessing the QT prolongation potential of a drug is typically done based on pivotal safety studies called thorough QT studies. Model-based estimation of the drug-induced QT prolongation at the estimated mean maximum drug concentration could increase efficiency over the currently used intersection-union test. However, robustness against model misspecification needs to be guaranteed in pivotal settings. The objective of this work was to develop an efficient, fully prespecified model-based inference method for thorough QT studies, which controls the type I error and provides satisfactory test power. This is achieved by model averaging: The proposed estimator of the concentration-response relationship is a weighted average of a parametric (linear) and a nonparametric (monotonic I-splines) estimator, with weights based on mean integrated square error. The desired properties of the method were confirmed in an extensive simulation study, which demonstrated that the proposed method controlled the type I error adequately, and that its power was higher than the power of the nonparametric method alone. The method can be extended from thorough QT studies to the analysis of QT data from pooled phase I studies.
Copyright © 2017 John Wiley & Sons, Ltd.

Keywords:  QT prolongation; concentration-response analysis; model averaging; thorough QT studies

Mesh:

Year:  2017        PMID: 28703360     DOI: 10.1002/sim.7395

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.

Authors:  Simon Buatois; Sebastian Ueckert; Nicolas Frey; Sylvie Retout; France Mentré
Journal:  AAPS J       Date:  2018-03-29       Impact factor: 4.009

2.  Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.

Authors:  Puneet Gaitonde; Yeamin Huh; Borje Darpo; Georg Ferber; Günter Heimann; James Li; Kaifeng Lu; Bernard Sebastien; Kuenhi Tsai; Steve Riley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-30       Impact factor: 2.745

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.